Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
TER
0.49% p.a.
Distribution policy
Accumulating
Replication
Physical
Fund size
CHF 24 m
Inception Date
23 January 2018
Holdings
36
Overview
Description
The L&G Pharma Breakthrough UCITS ETF seeks to track the Solactive Pharma Breakthrough Value index. The Solactive Pharma Breakthrough Value index tracks companies involved in the development and manufacturing of so-called "orphan drugs". Orphan drugs are drugs that target very rare diseases.
Documents
Chart
Basics
Data
| Index | Solactive Pharma Breakthrough Value |
| Investment focus | Equity, World, Health Care |
| Fund size | CHF 24 m |
| Total expense ratio | 0.49% p.a. |
| Replication | Physical (Full replication) |
| Legal structure | ETF |
| Investment approach | Long-only |
| Sustainability | No |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in CHF) | 18.63% |
| Inception/ Listing Date | 23 January 2018 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Ireland |
| Fund Provider | Legal & General (LGIM) |
| Fund Structure | Public Limited Company |
| UCITS compliance | Yes |
| Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
| Investment Advisor | Legal & General Investment Management Limited |
| Custodian Bank | The Bank of New York Mellon SA/NV, Dublin Branch |
| Revision Company | Ernst & Young |
| Fiscal Year End | 30 June |
| Swiss representative | First Independent Fund Services LTD |
| Swiss paying agent | NPB Neue Privat Bank AG |
| Germany | 30% tax rebate |
| Switzerland | ESTV Reporting |
| Austria | Tax Reporting Fund |
| UK | UK Reporting |
| Italy | 26.0% |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | BNY Mellon Fund Services (Ireland) Limited |
| Securities lending | Yes |
| Securities lending counterparty |
Similar ETFs
This section provides you with information on other ETFs with a similar investment focus to the L&G Pharma Breakthrough UCITS ETF.
Similar ETFs via ETF search
Similar ETFs via investment guides
How do you like our ETF profile? Here you'll find our Questionnaire.
Holdings
Below you find information about the composition of the L&G Pharma Breakthrough UCITS ETF.
Top 10 Holdings
Weight of top 10 holdings
out of 36
36.85%
| Xencor, Inc. | 5.74% |
| Travere Therapeutics | 5.58% |
| Halozyme Therapeutics | 3.57% |
| Xeris Biopharma Holdings | 3.33% |
| argenx | 3.32% |
| Ligand Pharmaceuticals, Inc. | 3.17% |
| Jazz Pharmaceuticals | 3.10% |
| Royalty Pharma | 3.07% |
| Incyte Corp. | 3.00% |
| Zevra Therapeutics | 2.97% |
Countries
| United States | 63.12% |
| Japan | 8.03% |
| Switzerland | 5.53% |
| Netherlands | 5.04% |
| Other | 18.28% |
Sectors
| Healthcare | 97.91% |
| Industrials | 2.02% |
| Other | 0.07% |
As of 27/08/2026
ETF Savings plan offers
Here you can find information about the savings plan availability of the ETF. You can use the table to compare all savings plan offers for the selected savings rate.
Select your savings amount:
| Broker | Rating | Execution fee | Account fee | |
|---|---|---|---|---|
 | 0.00 CHF | 0.00 CHF | View offer* | |
 | 0.00 CHF | 0.00 CHF | View offer* |
Detailed comparison of all offers
Source: justETF Research; as of 10/2026. The offers are sorted in the following way: 1. Rating 2. Execution fee 3. Number of ETF savings plans. In addition to the fees charged by online brokers, additional costs may apply. The stated fees are thus exclusive of standard market spreads, commissions, product costs and third-party fees. Please note: No guarantee can be given for the completeness, correctness and accuracy of the content listed. The information on the online brokers' homepages is decisive. Investments in securities involve risks.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable AG. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable AG. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
Performance
Returns overview
| YTD | +10.91% |
| 1 month | -0.99% |
| 3 months | -1.72% |
| 6 months | +10.29% |
| 1 year | +16.39% |
| 3 years | +32.60% |
| 5 years | +0.33% |
| Since inception (MAX) | +26.45% |
| 2025 | +19.69% |
| 2024 | +2.96% |
| 2023 | -18.55% |
| 2022 | -6.18% |
Monthly returns in a heat map
Risk
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risk overview
| Volatility 1 year | 18.59% |
| Volatility 3 years | 17.20% |
| Volatility 5 years | 17.68% |
| Return per risk 1 year | 0.88 |
| Return per risk 3 years | 0.57 |
| Return per risk 5 years | 0.00 |
| Maximum drawdown 1 year | -10.91% |
| Maximum drawdown 3 years | -21.13% |
| Maximum drawdown 5 years | -37.15% |
| Maximum drawdown since inception | -37.35% |
Rolling 1 year volatility
Stock exchange
Listings
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | ETLI | - - | - - | - |
| Borsa Italiana | EUR | BIOT | BIOT IM ETLIEUIV | ECBIOT.MI ETLIEURINAV=SOLA | Flow Traders B.V. |
| Euronext Amsterdam | EUR | BIOT | BIOT NA ETLIEUIV | GOBIOT.AS ETLIEURINAV=SOLA | Flow Traders B.V. |
| London Stock Exchange | GBX | BIGT | BIGT LN NA | BIGT.L NA | Flow Traders B.V. |
| London Stock Exchange | USD | BIOT | BIOT LN NA | GEBIOT.L NA | Flow Traders B.V. |
| SIX Swiss Exchange | CHF | BIOT | BIOT SW ETLIEUIV | BIOTC.S ETLIEURINAV=SOLA | Flow Traders B.V. |
| XETRA | EUR | ETLI | ETLI GY ETLIEUIV | ETLI.DE ETLIEURINAV=SOLA | Flow Traders B.V. |
Further information
Further ETFs with similar investment focus
| Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
|---|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF | 1,329 | 0.40% p.a. | Accumulating | Sampling |
| L&G Healthcare Technology & Innovation UCITS ETF USD Acc | 315 | 0.49% p.a. | Accumulating | Full replication |
| VanEck Genomics and Healthcare Innovators UCITS ETF A | 22 | 0.35% p.a. | Accumulating | Full replication |
Latest articles
Frequently asked questions
What is the name of BIOT?
The name of BIOT is L&G Pharma Breakthrough UCITS ETF.
What is the ticker of L&G Pharma Breakthrough UCITS ETF?
The primary ticker of L&G Pharma Breakthrough UCITS ETF is BIOT.
What is the ISIN of L&G Pharma Breakthrough UCITS ETF?
The ISIN of L&G Pharma Breakthrough UCITS ETF is IE00BF0H7608.
What are the costs of L&G Pharma Breakthrough UCITS ETF?
The total expense ratio (TER) of L&G Pharma Breakthrough UCITS ETF amounts to 0.49% p.a.. These costs are withdrawn continuously from the fund assets and already included in the performance of the ETF. You don't have to pay them separately. Please have a look at our article for more information about the cost of ETFs.
Is L&G Pharma Breakthrough UCITS ETF paying dividends?
L&G Pharma Breakthrough UCITS ETF is an accumulating ETF. This means that dividends are not distributed to investors. Instead, dividends are reinvested in the fund on the ex-date, which leads to an increase of the ETF's share price.
What's the fund size of L&G Pharma Breakthrough UCITS ETF?
The fund size of L&G Pharma Breakthrough UCITS ETF is 24m CHF. See the following article for more information about the size of ETFs.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable).
There is no warranty for completeness, accuracy and correctness for the displayed information. (en-CH)